Skip to main content

Advertisement

SpringerLink
Log in

Medical therapy of gliomas

  • Topic Review
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Medical therapies are an important part of adjunctive therapy for gliomas. In this chapter we will review the chemotherapeutic and targeted agents that have been evaluated in clinical trials in grade II–IV gliomas in the last decade. A number of randomized phase III trials were completed and reported. There has been a clear success in oligodendroglial tumors and low grade glioma. Although some progress has been made in glioblastoma, considerable work involving the multidisciplinary collaboration of basic science, translational and clinical investigators needs to be done to improve the outcome of patients with anaplastic astrocytoma and glioblastoma. In addition, tailoring treatment based on molecular cytogenetic characteristics is a major focus of research into precision based medicine for glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295–2305

    Article  PubMed  CAS  Google Scholar 

  2. Omuro AM, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6:1909–1919

    Article  PubMed  CAS  Google Scholar 

  3. Chang SM, Lamborn KR, Kuhn JG et al (2008) Neurooncology clinical trial design for targeted therapies: lessons learned from the North American brain tumor consortium. Neuro-Oncology 10:631–642

    Article  PubMed  PubMed Central  Google Scholar 

  4. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS (2009) Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 6:500–512

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Shaw EG, Wisoff JH (2003) Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro-Oncology 5:153–160

    Article  PubMed  PubMed Central  Google Scholar 

  6. Shaw EG, Wang M, Coons SW et al (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30:3065–3070

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Buckner JC, Pugh SL, Shaw EG (2014) Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low grade gliomas: RTOG 9802 with Alliance, ECOG, and SWOG. ASCO meeting abstracts 32:2001

  8. Pignatti F, van den Bent M, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084

    Article  PubMed  Google Scholar 

  9. Fisher BJ, Lui J, Macdonald DR et al (2013) A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: preliminary results of RTOG 0424. ASCO meeting abstracts 31:2008

  10. Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133–3138

    Article  PubMed  CAS  Google Scholar 

  11. Quinn JA, Reardon DA, Friedman AH et al (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646–651

    Article  PubMed  CAS  Google Scholar 

  12. van den Bent MJ, Taphoorn MJ, Brandes AA et al (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525–2528

    Article  PubMed  Google Scholar 

  13. Pace A, Vidiri A, Galie E et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14:1722–1726

    Article  PubMed  CAS  Google Scholar 

  14. Soffietti R, Ruda R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43:1066–1073

    Article  PubMed  CAS  Google Scholar 

  15. Stege EM, Kros JM, de Bruin HG et al (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103:802–809

    Article  PubMed  Google Scholar 

  16. Lebrun C, Fontaine D, Bourg V et al (2007) Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391–398

    Article  PubMed  CAS  Google Scholar 

  17. Buckner JC, Gesme D Jr, O’Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255

    Article  PubMed  CAS  Google Scholar 

  18. van den Bent MJ, Chinot O, Boogerd W et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14:599–602

    Article  PubMed  Google Scholar 

  19. Brada M, Viviers L, Abson C et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715–1721

    Article  PubMed  CAS  Google Scholar 

  20. Murphy PS, Viviers L, Abson C et al (2004) Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 90:781–786

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82:281–288

    Article  PubMed  CAS  Google Scholar 

  22. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p/19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861

    Article  PubMed  CAS  Google Scholar 

  23. Baumert BG, Mason WP, Ryan G et al (2013) Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). ASCO meeting abstracts 31:2007

  24. Chen YH, Gutmann DH (2014) The molecular and cell biology of pediatric low-grade gliomas. Oncogene 33:2019–2026

    Article  PubMed  CAS  Google Scholar 

  25. Wiencke JK, Zheng S, Jelluma N et al (2007) Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro-Oncology 9:271–279

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. McBride SM, Perez DA, Polley MY et al (2010) Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 97:33–40

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Johnson BE, Mazor T, Hong C et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189–193

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360–364

    Article  PubMed  CAS  Google Scholar 

  29. Cairncross G, Macdonald D, Ludwin S et al (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021

    PubMed  CAS  Google Scholar 

  30. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24:2707–2714

    Article  PubMed  CAS  Google Scholar 

  31. Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  32. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722

    Article  PubMed  Google Scholar 

  33. van den Bent MJ, Dubbink HJ, Sanson M et al (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881–5886

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kouwenhoven MC, Gorlia T, Kros JM et al (2009) Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-Oncology 11:737–746

    Article  PubMed  PubMed Central  Google Scholar 

  35. van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350

    Article  PubMed  Google Scholar 

  36. Vogelbaum MA, Berkey B, Peereboom D et al (2009) Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro-Oncology 11:167–175

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  37. Chinot OL, Honore S, Dufour H et al (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19:2449–2455

    PubMed  CAS  Google Scholar 

  38. Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S (1999) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17:3389–3395

    PubMed  CAS  Google Scholar 

  39. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018

    Article  PubMed  CAS  Google Scholar 

  40. (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19:509–518

  41. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880

    Article  PubMed  CAS  Google Scholar 

  42. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  43. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602

    Article  PubMed  CAS  Google Scholar 

  44. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  45. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771

    PubMed  CAS  Google Scholar 

  46. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    Article  PubMed  CAS  Google Scholar 

  47. Chamberlain MC, Johnston S (2009) Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 91:359–367

    Article  PubMed  CAS  Google Scholar 

  48. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  49. Clarke JL, Iwamoto FM, Sul J et al (2009) Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27:3861–3867

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–2057

    Article  PubMed  CAS  Google Scholar 

  51. Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085–4091

    Article  PubMed  CAS  Google Scholar 

  52. Chalmers AJ (2009) The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 89:23–40

    Article  PubMed  CAS  Google Scholar 

  53. Dungey FA, Loser DA, Chalmers AJ (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72:1188–1197

    Article  PubMed  CAS  Google Scholar 

  54. Sandhu SK, Yap TA, de Bono JS (2010) Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46:9–20

    Article  PubMed  CAS  Google Scholar 

  55. Malmstrom A, Gronberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase III trial. Lancet Oncol 13:916–926

    Article  PubMed  Google Scholar 

  56. Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase III trial. Lancet Oncol 13:707–715

    Article  PubMed  CAS  Google Scholar 

  57. Arvold ND, Reardon DA (2014) Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 9:357–367

    PubMed  PubMed Central  Google Scholar 

  58. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259

    Article  PubMed  CAS  Google Scholar 

  59. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Field KM, Simes J, Wheeler H et al (2013) A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). ASCO meeting abstracts 31:2017

  61. Taal W, Oosterkamp HM, Walenkamp AME et al (2013) A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. ASCO meeting abstracts2013 31:2001

  62. Lai A, Filka E, McGibbon B et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380

    Article  PubMed  CAS  Google Scholar 

  63. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708

    Article  PubMed  CAS  Google Scholar 

  64. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722

    Article  PubMed  CAS  Google Scholar 

  65. Herrlinger U, Schaefer N, Steinbach JP et al (2013) Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: first results from the randomized multicenter GLARIUS trial. ASCO meeting abstracts 31:LBA2000

  66. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  67. Batchelor TT, Mulholland P, Neyns B et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  68. de Groot JF, Lamborn KR, Chang SM et al (2011) Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29:2689–2695

    Article  PubMed  PubMed Central  Google Scholar 

  69. Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617

    Article  PubMed  CAS  Google Scholar 

  70. Stupp R, Hegi ME, Neyns B et al (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712–2718

    Article  PubMed  CAS  Google Scholar 

  71. Stupp R, Hegi ME, Gorlia T et al (2013) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. ASCO meeting abstracts 31:LBA2009

  72. Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  73. Wen PY, Prados M, Schiff D et al (2010) Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). ASCO meeting abstracts 28:2006

  74. Wick W, Steinbach JP, Platten M et al (2013) Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology 15:1405–1412

    Article  PubMed  CAS  Google Scholar 

  75. Prados MD, Yung WK, Jaeckle KA et al (2004) Phase I trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncology 6:44–54

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  76. Krishnan S, Brown PD, Ballman KV et al (2006) Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 65:1192–1199

    Article  PubMed  CAS  Google Scholar 

  77. Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142

    Article  PubMed  CAS  Google Scholar 

  78. van den Bent MJ, Brandes AA, Rampling R et al (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268–1274

    Article  PubMed  PubMed Central  Google Scholar 

  79. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    Article  PubMed  CAS  Google Scholar 

  80. Prados MD, Chang SM, Butowski N et al (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579–584

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  81. Brown PD, Krishnan S, Sarkaria JN et al (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26:5603–5609

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  82. Chakravarti A, Wang M, Robins HI et al (2013) RTOG 0211: a phase I/II study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 85:1206–1211

    Article  PubMed  CAS  Google Scholar 

  83. Eisenstat DD, Nabors LB, Mason WP et al (2011) A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. ASCO meeting abstracts 29:2010

  84. Chang SM, Wen P, Cloughesy T et al (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357–361

    Article  PubMed  CAS  Google Scholar 

  85. Cloughesy TF, Wen PY, Robins HI et al (2006) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24:3651–3656

    Article  PubMed  CAS  Google Scholar 

  86. Doherty L, Gigas DC, Kesari S et al (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156–158

    Article  PubMed  CAS  Google Scholar 

  87. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294–5304

    Article  PubMed  CAS  Google Scholar 

  88. Reardon DA, Desjardins A, Vredenburgh JJ et al (2010) Phase II trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219–230

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  89. Galanis E, Jaeckle KA, Maurer MJ et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052–2058

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  90. Kubicek GJ, Werner-Wasik M, Machtay M et al (2009) Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 74:433–439

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  91. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  92. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173

    Article  PubMed  CAS  Google Scholar 

  93. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  94. Dunn GP, Rinne ML, Wykosky J et al (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26:756–784

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  95. Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97–117

    Article  PubMed  CAS  Google Scholar 

  96. Yan H, Bigner DD, Velculescu V, Parsons DW (2009) Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69:9157–9159

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  97. Choi C, Ganji SK, DeBerardinis RJ et al (2012) 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624–629

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  98. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154

    Article  PubMed  CAS  Google Scholar 

  99. Leu S, von Felten S, Frank S et al (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncology 15:469–479

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  100. Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  101. Bettegowda C, Agrawal N, Jiao Y et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1455

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  102. Weiler M, Wick W (2012) Molecular predictors of outcome in low-grade glioma. Curr Opin Neurol 25:767–773

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

M.S.A. has received research support from Novartis, Boehringer Ingelheim. M.S.A. has served on advisory board for Genentech/Roche. S.M.C. has received research support from Novartis/Schering.

Author information

Authors and Affiliations

  1. The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

    Manmeet S. Ahluwalia

  2. Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, CA, USA

    Susan M. Chang

Authors
  1. Manmeet S. Ahluwalia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan M. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan M. Chang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahluwalia, M.S., Chang, S.M. Medical therapy of gliomas. J Neurooncol 119, 503–512 (2014). https://doi.org/10.1007/s11060-014-1495-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1495-1

Keywords

Search

Navigation